Background on the Situation
The Mexican pharmaceutical industry has long been facing unpaid debts from the federal government, with some dating back to 2019. According to the Health Commission of the Mexican Employers’ Confederation (CCE), these outstanding payments exceed 40,000 million pesos.
Government Efforts and Payments
Jorge Luis Caridad, president of the Mexican Association of Pharmaceutical Research Industries (AMIIF), expressed optimism about the current federal administration’s efforts to settle these debts. He stated, “We are seeing a very intense willingness and genuine intention from the government, especially in this latter part of the year, to catch up and schedule meetings to cover and reduce the outstanding payments to the industry.”
Claudia Sheinbaum, the president of Mexico City, recently announced that approximately 15,000 million pesos had been paid to pharmaceutical companies for overdue debts from previous years. These payments were made after verifying that all documentation was in order and medications had been delivered correctly.
Pharmaceutical Companies’ Perspectives
Daniel Londero, General Director of Bayer Pharmaceuticals Mexico, acknowledged that his company, along with others in the industry, still has pending payments from the government. Although he did not specify an amount at the time, Londero emphasized the federal administration’s commitment to regularizing payments and maintaining up-to-date records.
Juan Luis Moreno, Director of Pfizer Mexico, reported a gradual improvement in the situation. He highlighted the government’s efforts to enhance processes and communication, which has led to a positive outlook.
Sigfrido Rangel, Director Medical of GSK Mexico, mentioned that the government had recognized all outstanding debts, so there were no concerns regarding this matter. He expressed confidence that the pending issues would be resolved soon.
Industry Commitment and Future Outlook
Caridad, president of AMIIF, emphasized that affiliated companies are dedicated to ensuring an adequate supply of medications. He stressed the importance of advancing in settling debts, as pharmaceutical companies require resources to fulfill their purpose.
“We still have a journey ahead of us, and we will continue to work with the government in this manner,” Caridad noted.
Key Questions and Answers
- What is the total amount of outstanding debts owed by the federal government to the pharmaceutical industry? According to the Health Commission of the Mexican Employers’ Confederation (CCE), the total outstanding debt exceeds 40,000 million pesos.
- What efforts has the current federal administration made to address these debts? The government has shown a strong willingness and genuine intention to catch up on payments, scheduling meetings with the pharmaceutical industry to cover and reduce outstanding debts.
- How much has the government paid so far to pharmaceutical companies? Claudia Sheinbaum, the president of Mexico City, announced that around 15,000 million pesos had been paid to pharmaceutical companies for overdue debts from previous years.
- What is the current status of communication and collaboration between the government and pharmaceutical companies? Communication and collaboration between the government and pharmaceutical companies have been described as positive, with ongoing efforts to improve processes.
- Are there any remaining concerns about outstanding debts in the pharmaceutical industry? Industry leaders, such as Sigfrido Rangel of GSK Mexico, have expressed confidence that pending issues will be resolved soon.
